Sugi Predict

Sugi Predict / Targets / TRPM6

TRPM6

Transient receptor potential cation channel subfamily M member 6 · Q9BX84 · TRPM6 on Sugi Atlas →

2,185 patent compounds predicted against TRPM6, 1,721 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Tofacitinib Tofacitinib (SCHEMBL322753) 1.00 1/20
Tofacitinib Tofacitinib (SCHEMBL1120705) 1.00 1/20
Tofacitinib Tofacitinib (SCHEMBL11949309) 1.00 1/20
SCHEMBL2323500 SCHEMBL2323500 0.85 1/20
SCHEMBL3065509 SCHEMBL3065509 0.85 1/20
Tofacitinib Tofacitinib (SCHEMBL1374185) 0.83 1/20
Tofacitinib Tofacitinib (SCHEMBL6282362) 0.83 1/20
SCHEMBL2320931 SCHEMBL2320931 0.80 1/20
SCHEMBL3683647 SCHEMBL3683647 0.80 1/20
SCHEMBL4061609 SCHEMBL4061609 0.80 1/20
SCHEMBL12395122 SCHEMBL12395122 0.80 1/20
SCHEMBL4061567 SCHEMBL4061567 0.78 1/20
SCHEMBL5550913 SCHEMBL5550913 0.78 1/20
SCHEMBL1846276 SCHEMBL1846276 0.78 1/20
SCHEMBL4069759 SCHEMBL4069759 0.78 1/20
SCHEMBL9918576 SCHEMBL9918576 0.77 1/20
SCHEMBL2319641 SCHEMBL2319641 0.77 1/20
SCHEMBL3678056 SCHEMBL3678056 0.77 1/20
SCHEMBL4062773 SCHEMBL4062773 0.77 1/20
SCHEMBL4070029 SCHEMBL4070029 0.77 1/20

Clinical trials — most relevant to TRPM6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) PHASE4COMPLETED
Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls PHASE4COMPLETED
Investigator Initiated Trial Using Dry Eye Surveys to Evaluate and Better Understand FDA Approved Acoltremon Treatment for Dry Eye Disease in Real World Treatment Settings (DESERT) PHASE4NOT_YET_RECRUITING
TRPV Expression in Subjects With Sensitive Skin PHASE4UNKNOWN
The Re-Prosper HF Study PHASE2/PHASE3COMPLETED
TRPM8 Activators for Peripheral Neuropathy PHASE2ACTIVE_NOT_RECRUITING
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
Assessment of KM-001 - Safety, Tolerability, and Efficacy in Patients With PPPK1 or PC PHASE1COMPLETED
Study Designed to Evaluate Safety and Efficacy of 1% Topical Formulation of KM-001 on Type 1 Punctate Palmoplantar Keratoderma or Pachyonychia Congenita Diseases PHASE1COMPLETED
Do Acid Sensing Ion Channels Contribute to Heartburn? PHASE1COMPLETED
The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer PHASE1RECRUITING
Mechanisms of Human Heat Perception - Involvement of TRPA1, TRPV1 and TRPM3 EARLY_PHASE1COMPLETED
Mechanism of Human Cold Pain Perception - Involvement of TRPA1, TRPM8, Nav1.7 and Nav1.8 EARLY_PHASE1COMPLETED
Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1 EARLY_PHASE1RECRUITING
Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon. nanCOMPLETED
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Characterization of New Human Models of Non-histaminergic Itch and Their Interaction With the TRPM8 Receptor nanCOMPLETED
The Natural History of TRPV4 Neuropathy nanRECRUITING
An Investigation Into the Mechanism of Inhalation Cough Challenge nanCOMPLETED
TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients nanACTIVE_NOT_RECRUITING
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Neurogenic Mechanisms in Burning Mouth Syndrome nanCOMPLETED
Dissecting the Heterogeneity of Oral Cancer Pain nanUNKNOWN
Relationship Between Polymorphisms of TRPV1 and KCC2 Gene in Children With Febrile Seizures nanCOMPLETED
Effects of Photobiomodulation on the Innate Immune System of Neonates and Infants With Bronchiolitis nanUNKNOWN
A Study on the Mechanism of Cough Hypersensitivity nanUNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Mediators in Nasal Hyperreactivity in Allergic Rhinitis and Chronic Rhinosinusitis nanUNKNOWN
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy nanENROLLING_BY_INVITATION
Investigation of a New Human Model for Itch nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TRPM6 binder may also engage these)

ProteinNameSimilarity
Q8CIR4 — 1.000 Q8CIR4 →
Q925B3 — 1.000 Q925B3 →
A0A0R4IMY7 — 0.998 A0A0R4IMY7 →
Q9HCF6 — 0.996 Q9HCF6 →
Q7Z4N2 — 0.996 Q7Z4N2 →
Q923J1 — 0.995 Q923J1 →
TRPM7 Transient receptor potential cation channel subfamily M member 7 0.995 landscape →
J9SQF3 — 0.995 J9SQF3 →
Q2TV84 — 0.993 Q2TV84 →
Q2WEA5 — 0.990 Q2WEA5 →
S5UH55 — 0.990 S5UH55 →
A8DYE2 — 0.990 A8DYE2 →
Q8R455 — 0.984 Q8R455 →
TRPM8 Transient receptor potential cation channel subfamily M member 8 0.981 landscape →
Q8R4D5 — 0.981 Q8R4D5 →
Q8BTI9 — 0.977 Q8BTI9 →
Q62688 — 0.976 Q62688 →
Q6RI86 — 0.976 Q6RI86 →
Q8NHH9 — 0.975 Q8NHH9 →
Q6PA06 — 0.975 Q6PA06 →
O81211 — 0.975 O81211 →
Q9JJF9 — 0.975 Q9JJF9 →
Q3USB7 — 0.975 Q3USB7 →
O02697 — 0.975 O02697 →
Q58D72 — 0.974 Q58D72 →
Q91YH5 — 0.974 Q91YH5 →
Q8BLA8 — 0.974 Q8BLA8 →
Q6R8G6 — 0.974 Q6R8G6 →
ORC3 Origin recognition complex subunit 3 0.974 landscape →
Q7Z3F1 — 0.974 Q7Z3F1 →